ZC2HC1A is a zinc finger C2HC-type protein with protein binding capacity that has emerged as a potential prognostic biomarker across multiple cancer types. In hepatocellular carcinoma (HCC), ZC2HC1A was identified as one of nine genes in a prognostic signature associated with patient survival, where upregulation correlated with poor prognosis 1. The signature demonstrated strong predictive performance (concordance index 0.78-0.86) and successfully stratified HBV/HCV-infected patients into risk groups 1. Similarly, ZC2HC1A was selected as part of a 12-gene m6A-related signature panel for ovarian cancer prognosis, serving as an independent prognostic indicator (P=2.29E-18, HR=1.699) 2. Beyond cancer, ZC2HC1A was identified as a long non-coding RNA (ZC2HC1A-2) involved in regulating cytokine expression during Zika virus-infected macrophage responses, suggesting a role in inflammatory gene regulation 3. While these studies establish ZC2HC1A's clinical relevance as a prognostic marker and its involvement in inflammatory regulation, the precise molecular mechanisms underlying its protein function remain incompletely characterized. Further mechanistic studies are needed to understand how ZC2HC1A regulates gene expression and contributes to cancer progression and viral immunity.